Startups
Established in 1993, CMAX is one of Australia’s largest, longest running and most experienced, dedicated clinical trials unit.
Our team specialises in a range of early-phase clinical trials, including first-time in human-studies – of which we’ve conducted more than 100 to date.
With an impressive global regulatory history and a database of more than 13,000 active volunteers, our brand new 50-bed Phase I (through to Phase II-IV) unit includes a 24-bed ambulatory cardiac telemetry monitoring system and is centrally located to Adelaide’s Bio-med City.
All of our studies are fully ICH GCP compliant and comply with the registration requirements of the US FDA, EMEA, Japanese MHW and Canadian HPB; we have been US FDA-audited.
Our team specialises in a range of early-phase clinical trials, including first-time in human-studies – of which we’ve conducted more than 100 to date.
With an impressive global regulatory history and a database of more than 13,000 active volunteers, our brand new 50-bed Phase I (through to Phase II-IV) unit includes a 24-bed ambulatory cardiac telemetry monitoring system and is centrally located to Adelaide’s Bio-med City.
All of our studies are fully ICH GCP compliant and comply with the registration requirements of the US FDA, EMEA, Japanese MHW and Canadian HPB; we have been US FDA-audited.
Overview
Location
Australia, South Australia, Adelaide
Employees
51-200
Founded date
1993
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 27, 2025 | Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states | Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therap... |
| Aug 3, 2021 | Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment | Positive preclinical data suggests that Glyscend’s unique pill, mimicking gastric bypass surgery, will prove effective in treating type 2 diabetes |
Reviews 0
FAQ about CMAX Clinical Research
When was CMAX Clinical Research founded?
CMAX Clinical Research was founded in 1993.
What has the press written about CMAX Clinical Research?
Parsers VC has collected 3 articles mentioning CMAX Clinical Research, among them “Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states” (Aug 27, 2025) and “Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment” (Aug 3, 2021).
Is CMAX Clinical Research still active?
Yes, CMAX Clinical Research is active; its latest activity on Parsers VC dates from Sep 15, 2025.